What's the outlook for the Medibank share price in FY23?

Are Medibank shares the ticket to healthy returns?

| More on:
A women has her eyes checked at the optometrist.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Medibank is Australia's largest private health insurance business
  • It had a solid operating result in FY22 as claims remained low
  • Medibank is expecting further policyholder growth in FY23

The Medibank Private Ltd (ASX: MPL) share price has been volatile in recent months. It has managed to rise slightly in 2022 – up 3.5% – but since 30 August 2022 it's actually down by 5.6%.

The last three years have been an interesting time for private health insurance businesses.

There was a lot of disruption caused by the COVID-19 pandemic. But, that also led to a number of elective surgeries being delayed, which may have helped increase Medibank's profit during this period.

FY22 saw net resident policyholder growth of 60,900 (or 3.2%). Revenue rose 3.2%, with operating profit rising 12.5% to $594.1 million. However, the actual net profit after tax (NPAT) fell 10.7%. That was after the net investment income of $120 million in FY21 turned into a net investment expense of $24.8 million in FY22, as investment markets plummeted in the last few months of FY22.

Underlying NPAT, which aims to remove that investment volatility, rose by 9.1% to $435.1 million. The annual dividend per share increased 5.5% to 13.4 cents.

FY23 outlook

Growth within the business could have a positive effect on the Medibank share price.

In terms of FY23 policyholder growth, it's expecting a rise of 2.7%. That's assuming a modest decline in the growth rate of industry participation.

Looking at the comments about claims, it's expecting the underlying net claims expense per policy unit to grow. The growth rate of 2.3% in FY22 is its "best indicator" of growth in FY23 among resident policyholders.

The company expects productivity with its management expenses to largely offset the inflation of expenses.

In terms of customer relief, it continues "to assess claims activity and any permanent net claims savings due to COVID will be given back to customers through additional support in the future".

Management is focused on growth for the business. It's looking at both organic growth and acquisition opportunities for Medibank Health and health insurance, supported by a "strong capital position". It had health insurance business-related capital of $983.7 million at 30 June 2022, which was at the top end of its targeted range.

It has unallocated capital of $148 million, which "provides flexibility to fund future inorganic growth" and it will "consider further capital management if suitable opportunities do not arise".

What do experts think of the Medibank share price?

The brokers Citi and Ord Minnett both rate Medibank as a buy. Both brokers thought the FY22 result was good.

Ord Minnett has a price target of $3.75 on the business, which implies a possible rise of around 5% over the next year.

Meanwhile, Citi has a price target of $4. That suggests that the Medibank share price could rise by more than 10% over the next year.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares could rise 20% to 35%

These shares are being tipped to deliver market-beating returns by analysts.

Read more »

Keyboard button with the word sell on it.
Broker Notes

8 ASX All Ords stocks downgraded to sell ratings

Find out which shares are out of favour with the experts.

Read more »

Woman smiling whilst shopping in a clothing store.
Dividend Investing

Why this quality ASX 300 dividend stock is tipped to surge 54%

A leading fund manager forecasts significant outperformance from this quality ASX 300 dividend stock.

Read more »

A group of businesspeople clapping.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in June

These stocks could be best buys this month according to the broker.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Broker Notes

Why Macquarie forecasts this ASX All Ords media company is set to surge 19%

Up 42% in 2025, here’s why this ASX All Ords media stock could keep racing higher into 2026.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

Buy this ASX 200 stock for a 50% return: Bell Potter

Let's see why the broker is bullish on this name.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Leading broker tips 50%+ upside for IDP Education shares

The team at Macquarie thinks this beaten down stock could be a buy.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »